PIIINP
ZECEN
DR1031
| Quantity: | |
|---|---|
[INTENDED USE ]
The kit has been designed for the quantitative determination of Pepsinogen III N Terminal Peptide （PⅢNP）in human serum.
The method can be used for samples over the range of 4-700 ng/mL
Pepsinogen III N Terminal Peptide (PⅢNP) quantitative detection kit (CLIA) (hereinafter referred to as the kit) is used for in vitro quantitative detection of PⅢNP concentration in human serum.
PⅢNP can effectively reflect the synthesis of collagen type Ⅲ. Its serum levels consistent with the degree of liver fibrosis and significantly correlated with serum γ- globulin levels.
PⅢNP level is closely related with the activity of liver fibrosis which is valuable in the early diagnosis of liver fibrosis and the prognosis of chronic liver disease.
PⅢNP in normal liver is the amino terminus polypeptide generated by the amino-terminal peptide cleavage which is secreted by the PIII out of the liver cell before deposition. During this process, PⅢNP and Ⅲ type N-terminal peptide showed equal concentration, and entered into the blood circulation. Therefore, PⅢNP concentration can be an indicator to detect PⅢNP synthesis.
PⅢNP can be divided into four parts by chromatography: amino-terminal propeptide of 50KD, Coll of l0 KD (degradation part of the former), and the other two parts are the polymer propeptide dimer. With the development of liver fibrosis, PⅢNP of 50KD rises, and is with a positive correlation with the degree of cirrhosis, such as cirrhosis of the liver and liver fibrosis caused by virus and alcohol .
Therefore, LN, CIV, HA and PⅢNP become indicators for judgment of the severity of liver disease, to identify the presence or absence of cirrhosis and make prognosis. PⅢNP diagnosis is not initially detected, but in detecting the onset of a sustainable process. Diagnosis of liver fibrosis has been dependent on liver biopsy diagnosis, which has a number of significant deficiencies, for example, being traumatic, being difficult to repeat biopsies, certain complications (1/3 patients with pain; 0.3% patients with serious complications, including bleeding, pneumothorax, colon and gallbladder perforation; 0.03% mortality). Lesions in the liver are uneven, and there are differences between the viewer himself and between different viewers. Sample length is not enough (length <20mm and <10 pcs of portal area) which is prone to underestimate and broken specimens or subcapsular hepatic fibrosis can cause artifacts.
[INTENDED USE ]
The kit has been designed for the quantitative determination of Pepsinogen III N Terminal Peptide （PⅢNP）in human serum.
The method can be used for samples over the range of 4-700 ng/mL
Pepsinogen III N Terminal Peptide (PⅢNP) quantitative detection kit (CLIA) (hereinafter referred to as the kit) is used for in vitro quantitative detection of PⅢNP concentration in human serum.
PⅢNP can effectively reflect the synthesis of collagen type Ⅲ. Its serum levels consistent with the degree of liver fibrosis and significantly correlated with serum γ- globulin levels.
PⅢNP level is closely related with the activity of liver fibrosis which is valuable in the early diagnosis of liver fibrosis and the prognosis of chronic liver disease.
PⅢNP in normal liver is the amino terminus polypeptide generated by the amino-terminal peptide cleavage which is secreted by the PIII out of the liver cell before deposition. During this process, PⅢNP and Ⅲ type N-terminal peptide showed equal concentration, and entered into the blood circulation. Therefore, PⅢNP concentration can be an indicator to detect PⅢNP synthesis.
PⅢNP can be divided into four parts by chromatography: amino-terminal propeptide of 50KD, Coll of l0 KD (degradation part of the former), and the other two parts are the polymer propeptide dimer. With the development of liver fibrosis, PⅢNP of 50KD rises, and is with a positive correlation with the degree of cirrhosis, such as cirrhosis of the liver and liver fibrosis caused by virus and alcohol .
Therefore, LN, CIV, HA and PⅢNP become indicators for judgment of the severity of liver disease, to identify the presence or absence of cirrhosis and make prognosis. PⅢNP diagnosis is not initially detected, but in detecting the onset of a sustainable process. Diagnosis of liver fibrosis has been dependent on liver biopsy diagnosis, which has a number of significant deficiencies, for example, being traumatic, being difficult to repeat biopsies, certain complications (1/3 patients with pain; 0.3% patients with serious complications, including bleeding, pneumothorax, colon and gallbladder perforation; 0.03% mortality). Lesions in the liver are uneven, and there are differences between the viewer himself and between different viewers. Sample length is not enough (length <20mm and <10 pcs of portal area) which is prone to underestimate and broken specimens or subcapsular hepatic fibrosis can cause artifacts.
